Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad) Buy KYMR Stock  Free KYMR Stock Alerts

Kymera Therapeutics (KYMR) Financials

Kymera Therapeutics logo
$29.49 -0.68 (-2.25%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$29.10 -0.39 (-1.32%)
As of 05/23/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Kymera Therapeutics

Annual Income Statements for Kymera Therapeutics

This table shows Kymera Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -224 -147 -155 -100 -55 -41
Consolidated Net Income / (Loss)		 -224 -147 -155 -100 -46 -41
Net Income / (Loss) Continuing Operations		 -224 -147 -155 -100 -46 -40
Total Pre-Tax Income 		-224 -147 -155 -100 -46 -41
Total Operating Income		 -262 -166 -161 -101 -46 -42
Total Gross Profit		 47 79 47 73 34 2.93
Total Revenue		 47 79 47 73 34 2.93
Operating Revenue		 47 79 47 73 34 2.93
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 309 244 208 173 80 45
Selling, General & Admin Expense		 64 55 44 36 18 7.98
Research & Development Expense		 240 189 164 137 62 37
Impairment Charge		 4.93 0.00 0.00 - - -
Total Other Income / (Expense), net		 38 19 6.45 0.31 0.71 0.96
Other Income / (Expense), net		 38 19 6.45 0.31 0.71 0.96
Basic Earnings per Share		 ($2.98) ($2.52) ($2.87) ($2.09) ($3.15) ($24.28)
Weighted Average Basic Shares Outstanding		 75.04M 58.37M 53.93M 47.99M 17.35M 1.70M
Diluted Earnings per Share		 ($2.98) ($2.52) ($2.87) ($2.09) ($3.15) ($24.28)
Weighted Average Diluted Shares Outstanding		 75.04M 58.37M 53.93M 47.99M 17.35M 1.70M
Weighted Average Basic & Diluted Shares Outstanding		 64.94M 61.11M 55.18M 47.99M 17.35M 1.70M

Quarterly Income Statements for Kymera Therapeutics

This table shows Kymera Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -66 -71 -62 -42 -49 -14 -53 -39 -41 -35 -43
Consolidated Net Income / (Loss)		 -66 -71 -62 -42 -49 -14 -53 -39 -41 -35 -43
Net Income / (Loss) Continuing Operations		 -66 -71 -62 -42 -49 -14 -53 -39 -41 -35 -43
Total Pre-Tax Income 		-66 -71 -62 -42 -49 -14 -53 -39 -41 -35 -43
Total Operating Income		 -74 -81 -72 -51 -58 -19 -58 -43 -45 -39 -45
Total Gross Profit		 22 7.39 3.74 26 10 48 4.73 17 9.47 16 9.55
Total Revenue		 22 7.39 3.74 26 10 48 4.73 17 9.47 16 9.55
Operating Revenue		 22 7.39 3.74 26 10 48 4.73 17 9.47 16 9.55
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 97 88 76 77 68 67 62 60 55 55 54
Selling, General & Admin Expense		 16 16 15 17 14 14 14 14 13 12 11
Research & Development Expense		 80 72 60 59 49 53 48 46 42 43 44
Impairment Charge		 0.00 - 0.00 0.00 4.93 - 0.00 0.00 0.00 - -
Total Other Income / (Expense), net		 8.85 10 9.64 8.86 9.27 4.94 4.64 4.58 4.40 3.77 1.88
Other Income / (Expense), net		 8.85 10 9.64 8.86 9.27 4.94 4.64 4.58 4.40 3.77 1.88
Basic Earnings per Share		 ($0.82) ($0.89) ($0.82) ($0.58) ($0.69) ($0.25) ($0.90) ($0.67) ($0.70) ($0.59) ($0.79)
Weighted Average Basic Shares Outstanding		 80.15M 75.04M 76.13M 73.06M 70.77M 58.37M 58.42M 58.33M 58.19M 53.93M 54.54M
Diluted Earnings per Share		 ($0.82) ($0.89) ($0.82) ($0.58) ($0.69) ($0.25) ($0.90) ($0.67) ($0.70) ($0.59) ($0.79)
Weighted Average Diluted Shares Outstanding		 80.15M 75.04M 76.13M 73.06M 70.77M 58.37M 58.42M 58.33M 58.19M 53.93M 54.54M
Weighted Average Basic & Diluted Shares Outstanding		 65.12M 64.94M 64.77M 61.75M 61.36M 61.11M 55.49M 55.41M 55.31M 55.18M 54.86M

Annual Cash Flow Statements for Kymera Therapeutics

This table details how cash moves in and out of Kymera Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Change in Cash & Equivalents		 10 41 20 21 -45 36
Net Cash From Operating Activities		 -195 -103 -153 -129 88 18
Net Cash From Continuing Operating Activities		 -195 -103 -153 -129 88 18
Net Income / (Loss) Continuing Operations		 -224 -147 -155 -100 -46 -41
Consolidated Net Income / (Loss)		 -224 -147 -155 -100 -46 -41
Depreciation Expense		 7.37 3.57 2.98 2.40 1.76 0.83
Non-Cash Adjustments To Reconcile Net Income		 49 37 34 32 6.24 1.64
Changes in Operating Assets and Liabilities, net		 -27 3.91 -36 -63 126 57
Net Cash From Investing Activities		 -404 140 21 -100 -423 -16
Net Cash From Continuing Investing Activities		 -404 140 21 -100 -423 -16
Purchase of Property, Plant & Equipment		 -13 -34 -2.84 -1.60 -9.10 -0.53
Purchase of Investments		 -901 -189 -446 -456 -529 -16
Sale and/or Maturity of Investments		 510 364 469 358 116 0.00
Net Cash From Financing Activities		 609 4.19 153 250 289 35
Net Cash From Continuing Financing Activities		 609 4.19 153 250 289 35
Repayment of Debt		 -1.58 -0.08 -1.13 -0.85 -0.55 -0.37
Issuance of Common Equity		 12 2.86 153 0.79 183 0.00
Other Financing Activities, net		 599 1.41 1.15 9.98 14 0.07
Cash Interest Paid		 0.21 0.16 0.18 0.16 0.12 0.05

Quarterly Cash Flow Statements for Kymera Therapeutics

This table details how cash moves in and out of Kymera Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -30 9.55 43 -26 -16 29 29 1.89 -18 -87 79
Net Cash From Operating Activities		 -79 -62 -50 -43 -40 8.05 -32 -35 -44 -40 -34
Net Cash From Continuing Operating Activities		 -79 -62 -50 -43 -40 8.05 -32 -35 -44 -40 -35
Net Income / (Loss) Continuing Operations		 -66 -71 -62 -42 -49 -14 -53 -39 -41 -35 -43
Consolidated Net Income / (Loss)		 -66 -71 -62 -42 -49 -14 -53 -39 -41 -35 -43
Depreciation Expense		 2.05 1.99 1.99 1.94 1.46 0.89 0.90 0.90 0.88 0.82 0.77
Non-Cash Adjustments To Reconcile Net Income		 -7.35 9.02 14 10 16 9.64 11 8.96 7.28 8.87 7.88
Changes in Operating Assets and Liabilities, net		 -8.27 -2.04 -3.24 -13 -8.67 12 9.54 -6.32 -11 -14 -0.29
Net Cash From Investing Activities		 49 69 -158 16 -331 19 61 36 25 -50 -37
Net Cash From Continuing Investing Activities		 49 69 -158 16 -331 19 61 36 25 -50 -37
Purchase of Property, Plant & Equipment		 -0.47 -0.94 0.19 -4.69 -7.40 -12 -8.08 -11 -4.01 -0.37 -1.25
Purchase of Investments		 -84 -78 -296 -104 -423 -46 -29 -53 -62 -147 -154
Sale and/or Maturity of Investments		 133 148 138 124 99 76 98 99 90 98 118
Net Cash From Financing Activities		 0.26 2.77 251 1.41 354 1.93 -0.21 1.31 1.16 1.95 150
Net Cash From Continuing Financing Activities		 0.26 2.77 252 0.28 354 1.93 -0.21 1.31 1.16 1.95 150
Repayment of Debt		 -0.28 -0.29 -0.64 -0.35 -0.29 0.93 -0.34 -0.33 -0.33 -0.31 -0.29
Issuance of Common Equity		 0.54 -546 252 0.63 305 0.56 0.13 0.68 1.49 2.90 150
Other Financing Activities, net		 0.00 549 1.13 - 49 0.45 - 0.96 0.00 -0.64 0.96
Cash Interest Paid		 0.08 0.06 0.05 0.04 0.05 0.05 0.04 0.03 0.05 0.06 0.04

Annual Balance Sheets for Kymera Therapeutics

This table presents Kymera Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 978 576 603 606 487 117
Total Current Assets		 510 405 419 451 302 93
Cash & Equivalents		 120 110 68 48 31 76
Short-Term Investments		 368 265 339 394 265 16
Accounts Receivable		 0.00 15 0.00 0.00 0.58 0.00
Prepaid Expenses		 21 12 9.71 8.72 4.70 0.89
Other Current Assets		 0.95 3.76 2.54 0.14 0.86 0.00
Plant, Property, & Equipment, net		 50 48 13 12 11 3.79
Total Noncurrent Assets		 417 122 170 143 174 20
Long-Term Investments		 362 61 152 125 163 0.00
Other Noncurrent Operating Assets		 55 61 18 18 11 20
Total Liabilities & Shareholders' Equity		 978 576 603 606 487 117
Total Liabilities		 142 181 113 146 203 82
Total Current Liabilities		 68 86 71 93 111 35
Accounts Payable		 5.99 7.08 4.34 4.01 4.37 3.28
Accrued Expenses		 35 34 28 23 10 4.57
Current Deferred Revenue		 14 38 35 62 93 23
Other Current Liabilities		 13 6.87 4.25 3.83 3.37 3.38
Total Noncurrent Liabilities		 75 95 42 54 93 47
Noncurrent Deferred Revenue		 0.00 17 28 39 78 30
Other Noncurrent Operating Liabilities		 75 78 14 14 15 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 836 395 490 460 284 -74
Total Preferred & Common Equity		 836 395 490 460 284 -74
Total Common Equity		 836 395 490 460 284 -74
Common Stock		 1,592 926 879 689 413 2.04
Retained Earnings		 -755 -531 -384 -229 -129 -76
Accumulated Other Comprehensive Income / (Loss)		 -1.49 -0.55 -4.95 -0.66 -0.13 0.01

Quarterly Balance Sheets for Kymera Therapeutics

This table presents Kymera Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 918 1,035 826 868 552 582 614 638
Total Current Assets		 501 569 525 537 376 385 412 494
Cash & Equivalents		 90 111 68 94 81 52 50 156
Short-Term Investments		 373 439 442 427 277 315 347 326
Accounts Receivable		 0.00 0.00 0.00 0.00 - - - -
Prepaid Expenses		 18 17 14 15 14 14 11 9.23
Other Current Assets		 20 1.32 1.70 2.03 3.78 4.12 3.32 2.88
Plant, Property, & Equipment, net		 49 51 52 49 36 27 17 13
Total Noncurrent Assets		 368 415 249 282 141 169 185 132
Long-Term Investments		 312 361 192 224 77 105 119 114
Other Noncurrent Operating Assets		 56 54 56 57 64 64 66 18
Total Liabilities & Shareholders' Equity		 918 1,035 826 868 552 582 614 638
Total Liabilities		 132 142 141 157 157 147 152 126
Total Current Liabilities		 59 67 62 56 63 55 62 91
Accounts Payable		 10 6.49 6.51 6.81 4.98 3.75 6.48 6.33
Accrued Expenses		 23 27 24 16 26 22 19 25
Current Deferred Revenue		 11 20 19 23 27 24 32 56
Other Current Liabilities		 14 13 13 11 4.45 4.07 4.70 4.33
Total Noncurrent Liabilities		 73 75 79 101 94 92 90 34
Noncurrent Deferred Revenue		 0.00 0.00 3.19 24 16 20 25 21
Other Noncurrent Operating Liabilities		 73 75 76 77 77 71 65 13
Total Equity & Noncontrolling Interests		 786 893 685 711 396 435 462 513
Total Preferred & Common Equity		 786 893 685 711 396 435 462 513
Total Common Equity		 786 893 685 711 396 435 462 513
Common Stock		 1,606 1,575 1,308 1,292 914 903 890 868
Retained Earnings		 -820 -684 -621 -579 -516 -464 -425 -349
Accumulated Other Comprehensive Income / (Loss)		 -0.06 1.93 -2.10 -1.78 -2.45 -3.64 -3.04 -5.91

Annual Metrics And Ratios for Kymera Therapeutics

This table displays calculated financial ratios and metrics derived from Kymera Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Growth Metrics		 - - - - - -
Revenue Growth		 -40.11% 67.84% -35.71% 114.00% 1,059.99% 0.00%
EBITDA Growth		 -50.97% 5.55% -55.21% -123.18% -8.43% 0.00%
EBIT Growth		 -52.32% 5.07% -54.47% -119.81% -10.54% 0.00%
NOPAT Growth		 -58.06% -2.65% -60.41% -117.11% -9.71% 0.00%
Net Income Growth		 -52.32% 5.07% -54.47% -119.81% -10.54% 0.00%
EPS Growth		 -18.25% 12.20% -37.32% 33.65% 87.03% 0.00%
Operating Cash Flow Growth		 -89.16% 32.83% -18.72% -246.31% 392.21% 0.00%
Free Cash Flow Firm Growth		 -45.41% 5.04% -10.39% -261.19% 0.00% 0.00%
Invested Capital Growth		 63.03% 40.38% 35.77% 38.25% -205.23% 0.00%
Revenue Q/Q Growth		 -46.24% 67.77% 1.88% 3.54% 0.00% 0.00%
EBITDA Q/Q Growth		 -34.30% 12.55% -0.47% -27.58% 0.00% 0.00%
EBIT Q/Q Growth		 -33.67% 12.24% -0.55% -27.05% 0.00% 0.00%
NOPAT Q/Q Growth		 -30.69% 10.45% -2.96% -26.74% 0.00% 0.00%
Net Income Q/Q Growth		 -33.67% 12.24% -0.63% -26.85% 0.00% 0.00%
EPS Q/Q Growth		 -27.35% 11.89% 3.37% -116.02% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -56.01% 31.63% -0.78% -16.52% -9.51% 0.00%
Free Cash Flow Firm Q/Q Growth		 -29.67% 16.76% 2.16% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 15.44% -5.26% 16.18% 15.61% 0.00% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -459.90% -182.46% -324.25% -134.31% -128.78% -1,377.68%
Operating Margin		 -555.82% -210.62% -344.37% -138.03% -136.05% -1,438.48%
EBIT Margin		 -475.57% -186.99% -330.60% -137.60% -133.96% -1,405.79%
Profit (Net Income) Margin		 -475.57% -186.99% -330.60% -137.60% -133.96% -1,405.79%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -36.38% -33.21% -32.60% -26.96% -28.62% -118.95%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -28.81% -24.93% -25.61% -18.34% -15.10% -35.34%
Return on Assets (ROA)		 -28.81% -24.93% -25.61% -18.34% -15.10% -35.34%
Return on Common Equity (ROCE)		 -36.38% -33.21% -32.60% -26.96% -18.82% 255.26%
Return on Equity Simple (ROE_SIMPLE)		 -26.79% -37.21% -31.58% -21.80% -16.06% 55.43%
Net Operating Profit after Tax (NOPAT)		 -183 -116 -113 -70 -32 -30
NOPAT Margin		 -389.07% -147.43% -241.06% -96.62% -95.24% -1,006.94%
Net Nonoperating Expense Percent (NNEP)		 -6.33% -6.24% -7.44% -5.82% -4.79% -12.73%
Return On Investment Capital (ROIC_SIMPLE)		 -21.92% -29.34% -23.03% - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 134.97% 70.03% 93.61% 49.90% 53.57% 272.02%
R&D to Revenue		 510.38% 240.59% 350.76% 188.13% 182.48% 1,266.46%
Operating Expenses to Revenue		 655.82% 310.62% 444.37% 238.03% 236.05% 1,538.48%
Earnings before Interest and Taxes (EBIT)		 -224 -147 -155 -100 -46 -41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -216 -143 -152 -98 -44 -40
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 3.12 3.58 2.79 7.10 9.71 0.00
Price to Tangible Book Value (P/TBV)		 3.12 3.58 2.79 7.10 9.71 0.00
Price to Revenue (P/Rev)		 55.35 17.98 29.24 44.80 80.99 42.64
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 37.27 12.42 17.30 37.00 67.51 48.48
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 26.07 7.94
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 26.98 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.13 -1.19 -1.38 -1.73 -2.65
Leverage Ratio		 1.26 1.33 1.27 1.47 1.90 3.37
Compound Leverage Factor		 1.26 1.33 1.27 1.47 1.90 3.37
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 314.59%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% -214.59%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.73 3.36 6.30 13.14 8.00 -0.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 34.24% 314.59%
Liquidity Ratios		 - - - - - -
Current Ratio		 7.53 4.73 5.88 4.88 2.73 2.69
Quick Ratio		 7.21 4.55 5.71 4.78 2.68 2.66
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 -209 -144 -152 -137 85 0.00
Operating Cash Flow to CapEx		 -1,515.04% -298.22% -5,397.92% -8,074.26% 968.89% 3,365.60%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.06 0.13 0.08 0.13 0.11 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.95 2.56 3.71 6.41 4.65 0.77
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -15 -41 -69 -108 -175 -57
Invested Capital Turnover		 -1.66 -1.42 -0.53 -0.52 -0.29 -0.05
Increase / (Decrease) in Invested Capital		 26 28 39 67 -118 0.00
Enterprise Value (EV)		 1,755 976 810 2,695 2,298 142
Market Capitalization		 2,606 1,413 1,369 3,263 2,756 125
Book Value per Share		 $12.90 $7.12 $8.93 $8.94 $6.39 ($43.81)
Tangible Book Value per Share		 $12.90 $7.12 $8.93 $8.94 $6.39 ($43.81)
Total Capital		 836 395 490 460 284 35
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -851 -436 -559 -568 -459 -92
Capital Expenditures (CapEx)		 13 34 2.84 1.60 9.10 0.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -46 -55 -59 -84 -104 -34
Debt-free Net Working Capital (DFNWC)		 443 320 348 359 192 58
Net Working Capital (NWC)		 443 320 348 359 192 58
Net Nonoperating Expense (NNE)		 41 31 42 30 13 12
Net Nonoperating Obligations (NNO)		 -851 -436 -559 -568 -459 -92
Total Depreciation and Amortization (D&A)		 7.37 3.57 2.98 2.40 1.76 0.83
Debt-free, Cash-free Net Working Capital to Revenue		 -98.24% -70.31% -126.20% -114.90% -306.99% -1,147.99%
Debt-free Net Working Capital to Revenue		 940.05% 406.69% 743.33% 492.55% 563.32% 1,986.20%
Net Working Capital to Revenue		 940.05% 406.69% 743.33% 492.55% 563.32% 1,986.20%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 ($2.98) ($2.52) ($2.87) ($2.09) ($3.15) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 75.04M 58.37M 53.93M 51.70M 44.81M 0.00
Adjusted Diluted Earnings per Share		 ($2.98) ($2.52) ($2.87) ($2.09) ($3.15) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 75.04M 58.37M 53.93M 51.70M 44.81M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.09) ($3.15) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 64.94M 61.11M 55.18M 47.99M 17.35M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -180 -116 -113 -70 -32 -30
Normalized NOPAT Margin		 -381.75% -147.43% -241.06% -96.62% -95.24% -1,006.94%
Pre Tax Income Margin		 -475.57% -186.99% -330.60% -137.60% -133.96% -1,405.79%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Kymera Therapeutics

This table displays calculated financial ratios and metrics derived from Kymera Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 114.83% -84.56% -20.88% 55.33% 8.67% 196.70% -50.50% 43.42% -1.62% 5.66% -53.03%
EBITDA Growth		 -34.90% -410.24% -16.41% -5.87% -17.60% 60.42% -23.05% 4.18% -11.26% -2.13% -51.62%
EBIT Growth		 -35.06% -392.43% -18.20% -8.41% -18.64% 58.79% -22.94% 3.62% -11.57% -2.47% -50.74%
NOPAT Growth		 -28.70% -318.16% -25.41% -17.38% -27.59% 50.01% -28.13% -6.30% -22.72% -13.64% -56.73%
Net Income Growth		 -35.06% -392.43% -18.20% -8.41% -18.64% 58.79% -22.94% 3.62% -11.57% -2.85% -50.45%
EPS Growth		 -18.84% -256.00% 8.89% 13.43% 1.43% 57.63% -13.92% 14.10% 1.41% 14.49% -41.07%
Operating Cash Flow Growth		 -99.92% -867.98% -58.59% -21.78% 9.96% 120.35% 7.65% 9.57% -9.12% -3.09% 8.03%
Free Cash Flow Firm Growth		 -59.26% -98.93% 14.35% 29.39% 16.25% 36.77% -9.22% 13.65% 20.61% 27.58% 2.65%
Invested Capital Growth		 131.86% 63.03% 53.98% 52.65% 37.41% 40.38% 52.52% 56.35% 43.02% 35.77% 35.34%
Revenue Q/Q Growth		 198.89% 97.65% -85.42% 149.34% -78.52% 912.80% -71.37% 74.45% -41.35% 68.98% -17.05%
EBITDA Q/Q Growth		 7.61% -13.66% -50.78% 14.80% -249.45% 74.07% -37.13% 5.37% -17.63% 19.39% -6.78%
EBIT Q/Q Growth		 7.31% -13.23% -48.56% 13.38% -237.95% 72.82% -36.26% 5.20% -17.39% 18.92% -6.82%
NOPAT Q/Q Growth		 7.84% -11.97% -41.63% 11.94% -199.46% 66.42% -32.56% 4.29% -17.33% 13.93% -9.98%
Net Income Q/Q Growth		 7.31% -13.23% -48.56% 13.38% -237.95% 72.82% -36.26% 5.20% -17.39% 18.92% -6.82%
EPS Q/Q Growth		 7.87% -8.54% -41.38% 15.94% -176.00% 72.22% -34.33% 4.29% -18.64% 25.32% -1.28%
Operating Cash Flow Q/Q Growth		 -28.11% -23.10% -16.89% -8.45% -592.12% 125.42% 10.24% 19.81% -11.21% -15.37% 12.10%
Free Cash Flow Firm Q/Q Growth		 -16.94% -15.20% -30.16% 9.17% -46.06% 50.40% -7.31% -7.73% -10.27% 14.32% 15.16%
Invested Capital Q/Q Growth		 170.32% 15.44% -3.44% 48.20% 18.41% -5.26% -6.43% 31.52% 22.29% 16.18% 2.15%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -287.48% -930.01% -1,617.21% -156.43% -457.82% -28.14% -1,099.24% -229.51% -423.08% -210.96% -442.21%
Operating Margin		 -336.77% -1,092.17% -1,927.93% -198.54% -562.18% -40.33% -1,216.35% -262.72% -478.83% -239.36% -469.92%
EBIT Margin		 -296.75% -956.88% -1,670.33% -163.98% -472.02% -30.01% -1,118.17% -234.96% -432.37% -216.03% -450.24%
Profit (Net Income) Margin		 -296.75% -956.88% -1,670.33% -163.98% -472.02% -30.01% -1,118.17% -234.96% -432.37% -216.03% -450.24%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.17% -36.38% -26.00% -28.18% -26.35% -33.21% -36.87% -37.82% -35.71% -32.60% -30.89%
Cash Return on Invested Capital (CROIC)		 -2,225.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -19.56% -57.98% -184.30% -20.63% -50.58% -4.00% -87.97% -21.97% -34.29% -16.73% -32.31%
Return on Assets (ROA)		 -19.56% -57.98% -184.30% -20.63% -50.58% -4.00% -87.97% -21.97% -34.29% -16.73% -32.31%
Return on Common Equity (ROCE)		 -32.17% -36.38% -26.00% -28.18% -26.35% -33.21% -36.87% -37.82% -35.71% -32.60% -30.89%
Return on Equity Simple (ROE_SIMPLE)		 -30.64% 0.00% -18.76% -23.05% -21.74% 0.00% -42.34% -36.19% -34.43% 0.00% -30.00%
Net Operating Profit after Tax (NOPAT)		 -52 -57 -50 -36 -40 -14 -40 -30 -32 -27 -31
NOPAT Margin		 -235.74% -764.52% -1,349.55% -138.98% -393.52% -28.23% -851.44% -183.90% -335.18% -167.56% -328.94%
Net Nonoperating Expense Percent (NNEP)		 -1.77% -2.21% -1.78% -1.09% -1.28% -0.17% -2.45% -1.77% -1.77% -1.39% -1.92%
Return On Investment Capital (ROIC_SIMPLE)		 -6.63% -6.76% - - - -3.42% - - - -5.52% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 73.62% 220.88% 413.12% 67.73% 139.73% 29.71% 298.65% 85.56% 132.74% 72.10% 110.52%
R&D to Revenue		 363.14% 971.29% 1,614.81% 230.81% 474.57% 110.62% 1,017.70% 277.16% 446.09% 267.27% 459.40%
Operating Expenses to Revenue		 436.77% 1,192.17% 2,027.93% 298.54% 662.18% 140.33% 1,316.35% 362.72% 578.83% 339.36% 569.92%
Earnings before Interest and Taxes (EBIT)		 -66 -71 -62 -42 -49 -14 -53 -39 -41 -35 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -64 -69 -61 -40 -47 -13 -52 -38 -40 -34 -42
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.26 3.12 3.27 2.67 3.14 3.58 1.95 2.92 3.54 2.79 2.20
Price to Tangible Book Value (P/TBV)		 2.26 3.12 3.27 2.67 3.14 3.58 1.95 2.92 3.54 2.79 2.20
Price to Revenue (P/Rev)		 30.19 55.35 33.38 20.68 28.09 17.98 16.44 24.61 35.04 29.24 24.57
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 93.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 17.02 37.27 22.98 12.75 18.71 12.42 7.16 15.47 23.98 17.30 11.61
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.05 -1.04 -1.05 -1.07 -1.13 -1.13 -1.15 -1.17 -1.19 -1.21
Leverage Ratio		 1.19 1.26 1.23 1.26 1.26 1.33 1.31 1.33 1.32 1.27 1.29
Compound Leverage Factor		 1.19 1.26 1.23 1.26 1.26 1.33 1.31 1.33 1.32 1.27 1.29
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.23 10.25 11.90 7.35 8.16 4.12 2.09 4.64 6.03 6.96 5.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.49 7.53 8.55 8.45 9.57 4.73 5.95 7.06 6.65 5.88 5.42
Quick Ratio		 7.85 7.21 8.27 8.21 9.27 4.55 5.66 6.73 6.41 5.71 5.29
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -97 -83 -72 -55 -61 -42 -84 -78 -72 -66 -77
Operating Cash Flow to CapEx		 -16,948.61% -6,600.85% 0.00% -915.68% -534.87% 69.20% -391.77% -327.41% -1,096.73% -10,599.46% -2,750.32%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.07 0.06 0.11 0.13 0.11 0.13 0.08 0.09 0.08 0.08 0.07
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.20 0.95 2.00 2.24 2.38 2.56 1.92 2.57 3.20 3.71 3.71
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 -15 -18 -17 -34 -41 -39 -37 -54 -69 -83
Invested Capital Turnover		 -5.12 -1.66 -3.05 -3.26 -1.81 -1.42 -0.77 -0.85 -0.63 -0.53 -0.44
Increase / (Decrease) in Invested Capital		 44 26 21 19 20 28 43 48 41 39 45
Enterprise Value (EV)		 1,002 1,755 2,012 1,129 1,486 976 335 799 1,119 810 533
Market Capitalization		 1,778 2,606 2,923 1,832 2,231 1,413 770 1,272 1,635 1,369 1,129
Book Value per Share		 $12.11 $12.90 $14.46 $11.16 $10.05 $7.12 $7.14 $7.87 $8.37 $8.93 $9.89
Tangible Book Value per Share		 $12.11 $12.90 $14.46 $11.16 $10.05 $7.12 $7.14 $7.87 $8.37 $8.93 $9.89
Total Capital		 786 836 893 685 711 395 396 435 462 490 513
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -775 -851 -911 -702 -745 -436 -435 -472 -516 -559 -596
Capital Expenditures (CapEx)		 0.47 0.94 -0.19 4.69 7.40 12 8.08 11 4.01 0.37 1.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -21 -46 -48 -47 -39 -55 -45 -37 -47 -59 -79
Debt-free Net Working Capital (DFNWC)		 442 443 502 463 481 320 313 331 350 348 403
Net Working Capital (NWC)		 442 443 502 463 481 320 313 331 350 348 403
Net Nonoperating Expense (NNE)		 13 14 12 6.41 8.08 0.85 13 8.43 9.20 7.82 12
Net Nonoperating Obligations (NNO)		 -775 -851 -911 -702 -745 -436 -435 -472 -516 -559 -596
Total Depreciation and Amortization (D&A)		 2.05 1.99 1.99 1.94 1.46 0.89 0.90 0.90 0.88 0.82 0.77
Debt-free, Cash-free Net Working Capital to Revenue		 -35.98% -98.24% -54.57% -52.73% -49.65% -70.31% -96.69% -71.17% -101.26% -126.20% -171.90%
Debt-free Net Working Capital to Revenue		 750.55% 940.05% 573.51% 523.17% 605.84% 406.69% 667.14% 640.23% 749.13% 743.33% 876.59%
Net Working Capital to Revenue		 750.55% 940.05% 573.51% 523.17% 605.84% 406.69% 667.14% 640.23% 749.13% 743.33% 876.59%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.82) ($0.89) ($0.82) ($0.58) ($0.69) ($0.25) ($0.90) ($0.67) ($0.70) ($0.59) ($0.79)
Adjusted Weighted Average Basic Shares Outstanding		 80.15M 75.04M 76.13M 73.06M 70.77M 58.37M 58.42M 58.33M 58.19M 53.93M 54.54M
Adjusted Diluted Earnings per Share		 ($0.82) ($0.89) ($0.82) ($0.58) ($0.69) ($0.25) ($0.90) ($0.67) ($0.70) ($0.59) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding		 80.15M 75.04M 76.13M 73.06M 70.77M 58.37M 58.42M 58.33M 58.19M 53.93M 54.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 65.12M 64.94M 64.77M 61.75M 61.36M 61.11M 55.49M 55.41M 55.31M 55.18M 54.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -52 -57 -50 -36 -37 -14 -40 -30 -32 -27 -31
Normalized NOPAT Margin		 -235.74% -764.52% -1,349.55% -138.98% -360.01% -28.23% -851.44% -183.90% -335.18% -167.56% -328.94%
Pre Tax Income Margin		 -296.75% -956.88% -1,670.33% -163.98% -472.02% -30.01% -1,118.17% -234.96% -432.37% -216.03% -450.24%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Kymera Therapeutics' Financials

When does Kymera Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Kymera Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Kymera Therapeutics' net income changed over the last 5 years?

Kymera Therapeutics' net income appears to be on an upward trend, with a most recent value of -$223.86 million in 2024, rising from -$41.25 million in 2019. The previous period was -$146.96 million in 2023. See where experts think Kymera Therapeutics is headed by visiting Kymera Therapeutics' forecast page.

What is Kymera Therapeutics's operating income?
Kymera Therapeutics's total operating income in 2024 was -$261.64 million, based on the following breakdown:
  • Total Gross Profit: $47.07 million
  • Total Operating Expenses: $308.71 million
How has Kymera Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Kymera Therapeutics' total revenue changed from $2.93 million in 2019 to $47.07 million in 2024, a change of 1,504.4%.

How much debt does Kymera Therapeutics have?

Kymera Therapeutics' total liabilities were at $142.42 million at the end of 2024, a 21.2% decrease from 2023, and a 73.6% increase since 2019.

How much cash does Kymera Therapeutics have?

In the past 5 years, Kymera Therapeutics' cash and equivalents has ranged from $31.00 million in 2020 to $120.26 million in 2024, and is currently $120.26 million as of their latest financial filing in 2024.

How has Kymera Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Kymera Therapeutics' book value per share changed from -43.81 in 2019 to 12.90 in 2024, a change of -129.5%.


Related Companies

This page (NASDAQ:KYMR) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
The one deadline Elon can't afford to miss...
For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...
Brownstone Research | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored